In yesterday’s Wall Street session, Edwards Lifesciences Corporation (NYSE:EW) shares traded at $78.79, down -1.34% from the previous session.
As of this writing, 30 analysts cover Edwards Lifesciences Corporation (NYSE:EW). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $110.00 and a low of $75.00, we find $99.00. Given the previous closing price of $79.86, this indicates a potential upside of 23.97 percent. EW stock price is now -10.03% away from the 50-day moving average and -3.19% away from the 200-day moving average. The market capitalization of the company currently stands at $47.22B.
There are 13 analysts who have given it a hold rating, whereas 13 have given it a buy rating. Brokers who have rated the stock have averaged $97.09 as their price target over the next twelve months.
With the price target of $107, Robert W. Baird recently initiated with Outperform rating for Edwards Lifesciences Corporation (NYSE: EW).
In other news, Wood Larry L, Global President TAVR & Surg sold 6,421 shares of the company’s stock on Aug 14. The stock was sold for $509,185 at an average price of $79.30. Upon completion of the transaction, the Global President TAVR & Surg now directly owns 213,794 shares in the company, valued at $16.84 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 14, CVP,Strategy/Corp Development BOBO DONALD E JR sold 4,500 shares of the business’s stock. A total of $356,850 was realized by selling the stock at an average price of $79.30. This leaves the insider owning 39,503 shares of the company worth $3.11 million. Insiders disposed of 820,033 shares of company stock worth roughly $64.61 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corporation shares was purchased by STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD during the first quarter worth $95,455,000. BOWEN HANES & CO INC invested $27,982,000 in shares of EW during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Edwards Lifesciences Corporation valued at approximately $15,777,000. ALPHINITY INVESTMENT MANAGEMENT PTY LTD acquired a new stake in EW for approximately $13,930,000. RETIREMENT SYSTEMS OF ALABAMA purchased a new stake in EW valued at around $10,856,000 in the second quarter. In total, there are 1,798 active investors with 84.90% ownership of the company’s stock.
Wednesday morning saw Edwards Lifesciences Corporation (NYSE: EW) opened at $79.22. During the past 12 months, Edwards Lifesciences Corporation has had a low of $67.13 and a high of $104.12. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 3.20, and a quick ratio of 2.30. According to the stock market information, the enterprise value for the company is $47.72B, which is based on a 34.91 price-to-earnings ratio, a 3.61 price-to-earnings-growth ratio, and a beta of 1.02. The fifty day moving average price for EW is $87.43 and a two-hundred day moving average price translates $81.35 for the stock.
The latest earnings results from Edwards Lifesciences Corporation (NYSE: EW) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at $0.66, beating analysts’ expectations of $0.65 by 0.01. This compares to $0.65 EPS in the same period last year. The net profit margin was 24.60% and return on equity was 22.80% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.37 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.38 percent. For the current quarter, analysts expect EW to generate $1.48B in revenue.
